Full text
Earnings transcript
Read the complete earnings call transcript.
4523
4523.T
Eisai Co., Ltd.
$3991
42
(1.06%)
| Exchange: | JPX |
| Market Cap: | 1.126T |
| Shares Outstanding: | 286.616M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – Specialty & Generic | |||||
| CEO: | Haruo Naito | |||||
| Full Time Employees: | 11067 | |||||
| Address: |
| |||||
| Website: | https://www.eisai.co.jp |
Eisai Co., Ltd. is a Japanese pharmaceutical firm that develops, manufactures, and markets a broad spectrum of medical and healthcare products. Its significant therapeutic contributions include Aricept, prescribed for individuals with Alzheimer’s disease and dementia with Lewy bodies; Methycobal, targeting peripheral neuropathy; and Fycompa, an antiepileptic medication used as an adjunctive treatment for partial-onset and primary generalized tonic-clonic seizures. The company’s product line further encompasses Lyrica for pain management, and Dayvigo, an anti-insomnia agent formulated for adults. In the field of oncology, Eisai offers Lenvima, a molecularly targeted anticancer drug utilized for thyroid cancer, renal cell carcinoma (when administered alongside everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, an anticancer agent functioning as a microtubule dynamics inhibitor, indicated for breast cancer and liposarcoma. Additionally, Eisai provides Pariet, a proton-pump inhibitor effective in managing gastric and duodenal ulcers, reflux esophagitis, and the eradication of Helicobacter pylori infections. It also distributes Humira, a fully human anti-TNF-alpha monoclonal antibody employed in the treatment of autoimmune disorders such as rheumatoid arthritis. For consumer wellness, its offerings include Chocola BB plus, a vitamin B2 supplement beneficial for rough skin and stomatitis, along with a diverse collection of other items, such as third-class over-the-counter (OTC) drugs, designated quasi-drugs, and health-promoting foods. Originally established in 1941 under the name Nihon Eisai Co., Ltd., the company adopted its current name, Eisai Co., Ltd., in 1955 and operates from its headquarters in Tokyo, Japan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 741,751,000 | 789,400,000 | 825,378,000 |
| Gross Profit | 563,774,000 | 597,233,000 | 634,155,000 |
| EBITDA | 103,105,000 | 103,727,000 | 95,884,000 |
| Operating Income | 46,752,000 | 49,240,000 | 40,208,000 |
| Net Income | 42,407,000 | 46,433,000 | 38,558,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,393,799,000 | 1,386,547,000 | 1,449,113,000 |
| Total Liabilities | 494,825,000 | 520,577,000 | 523,990,000 |
| Total Stockholders Equity | 875,614,000 | 841,417,000 | 898,992,000 |
| Total Debt | 206,746,000 | 231,175,000 | 186,081,000 |
| Cash and Cash Equivalents | 304,678,000 | 265,561,000 | 245,423,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 55,993,000 | 30,117,000 | 61,323,000 |
| Capital Expenditure | -14,321,000 | -11,933,000 | -15,359,000 |
| Free Cash Flow | 41,672,000 | 18,184,000 | 45,964,000 |
| Net Income | 42,407,000 | 46,433,000 | 38,558,000 |
| Net Change in Cash | 37,328,000 | -39,117,000 | -20,138,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 968,306,951.660 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,051,430,814.387 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,007,605,666.667 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 121,777,798.074 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 132,231,756.865 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 126,720,147.163 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 68,591,459.548 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 76,340,471.912 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 72,254,983.750 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 474,373,413.822 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 515,095,780.282 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 493,625,847.737 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 256.320 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 270.820 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 243.330 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 7 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 8 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about 4523.T valuation
Is Eisai Co., Ltd. (4523.T) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Eisai Co., Ltd. (4523.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is 4523.T a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4523.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is 4523.T’s P/E ratio?
You can see 4523.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for 4523.T?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is 4523.T a good long-term investment?
Whether 4523.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
4523.T
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.06
Trading Metrics:
| Open: | 3952 | Previous Close: | 3949 | |
| Day Low: | 3940 | Day High: | 4009 | |
| Year Low: | 3660 | Year High: | 5349 | |
| Price Avg 50: | 4247.84 | Price Avg 200: | 4638.72 | |
| Volume: | 1.621M | Average Volume: | 1.575M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free